{{PBB|geneid=2641}}
'''Glucagon''', a peptide [[hormone]] secreted by the [[pancreas]], raises blood glucose levels. Its effect is opposite that of [[insulin]], which lowers blood glucose levels.<ref name="Campbell">{{cite book | author = Reece J, Campbell N | authorlink = | editor = | others = | title = Biology | edition = | language = | publisher = Benjamin Cummings | location = San Francisco | year = 2002 | origyear = | pages = | quote = | isbn = 0-8053-6624-5 | oclc = | doi = | url = | accessdate = }}</ref> The pancreas releases glucagon when [[blood sugar]] (glucose) levels fall too low. Glucagon causes the [[liver]] to convert stored [[glycogen]] into [[glucose]], which is released into the bloodstream. High blood glucose levels stimulate the release of insulin.  Insulin allows glucose to be taken up and used by insulin-dependent tissues. Thus, glucagon and insulin are part of a feedback system that keeps blood glucose levels at a stable level. Glucagon belongs to  [[Glucagon hormone family|a family of several other related hormones]].

==Physiology==

===Production===
The hormone is synthesized and secreted from [[alpha cell]]s (α-cells) of the [[islets of Langerhans]], which are located in the endocrine portion of the pancreas. In rodents, the alpha cells are located in the outer rim of the islet. Human islet structure is much less segregated, and alpha cells are distributed throughout the islet.

===Regulation===
Secretion of glucagon is '''stimulated''' by:
* Hypoglycemia
* [[Epinephrine]] (via β2, α2,<ref name="Layden_2010">{{cite journal | author = Layden BT, Durai V, Lowe WL | title = G-Protein-Coupled Receptors, Pancreatic Islets, and Diabetes | journal = Nature Education | volume = 3 | issue = 9 | pages = 13 | year = 2010 | url = http://www.nature.com/scitable/topicpage/g-protein-coupled-receptors-pancreatic-islets-and-14257267 }}</ref> and α1<ref name=alpha1and2>{{cite journal | author = Skoglund G, Lundquist I, Ahrén B | title = Alpha 1- and alpha 2-adrenoceptor activation increases plasma glucagon levels in the mouse | journal = Eur. J. Pharmacol. | volume = 143 | issue = 1 | pages = 83–8 | year = 1987 | month = November | pmid = 2891547 | doi = 10.1016/0014-2999(87)90737-0 }}</ref> adrenergic receptors)
* [[Arginine]]
* [[Alanine]] (often from muscle-derived pyruvate/glutamate transamination (see [[alanine transaminase]] reaction).
* [[Acetylcholine]]<ref name="HoneyWEIRf1980">{{cite journal | author = Honey RN, Weir GC | title = Acetylcholine stimulates insulin, glucagon, and somatostatin release in the perfused chicken pancreas | journal = Endocrinology | volume = 107 | issue = 4 | pages = 1065–8 | year = 1980 | month = October | pmid = 6105951 | doi = 10.1210/endo-107-4-1065 }}</ref>
* [[Cholecystokinin]]

Secretion of glucagon is '''inhibited''' by:
* [[Somatostatin]]
* [[Insulin]] (via [[GABA]])<ref name="pmid16399504">{{cite journal | author = Xu E, Kumar M, Zhang Y, Ju W, Obata T, Zhang N, Liu S, Wendt A, Deng S, Ebina Y, Wheeler MB, Braun M, Wang Q | title = Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system | journal = Cell Metab. | volume = 3 | issue = 1 | pages = 47–58 | year = 2006 | month = January | pmid = 16399504 | doi = 10.1016/j.cmet.2005.11.015 }}</ref>
* Increased free [[fatty acids]] and [[keto acids]] into the blood
* Increased [[urea]] production

===Function===
[[Image:Glucagon rednblue.png|thumb|left|A microscopic image stained for glucagon]]
Glucagon generally elevates the amount of [[glucose]] in the [[blood]] by promoting [[gluconeogenesis]] and [[glycogenolysis]]. 
{{drugbox
| Verifiedfields = correct
| verifiedrevid = 461121086
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 76LA80IG2G
| name = 
| IUPAC_name        = 
| image             = Glucagon.png|thumb|right|Glucagon ball and stick model, with the [[carboxyl]] terminus above and the [[amino]] terminus below]
| alt               = 
| caption = 
| tradename =  
| Drugs.com =
| MedlinePlus =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10481928
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C153H225N43O49S/c1-72(2)52-97(133(226)176-96(47-51-246-11)132(225)184-104(60-115(159)209)143(236)196-123(78(10)203)151(244)245)179-137(230)103(58-83-64-167-89-29-19-18-28-87(83)89)183-131(224)95(43-46-114(158)208)177-148(241)120(74(5)6)194-141(234)101(54-79-24-14-12-15-25-79)182-138(231)105(61-117(211)212)185-130(223)94(42-45-113(157)207)171-124(217)75(7)170-127(220)91(31-22-49-165-152(160)161)172-128(221)92(32-23-50-166-153(162)163)174-146(239)110(69-199)191-140(233)107(63-119(215)216)186-134(227)98(53-73(3)4)178-135(228)99(56-81-33-37-85(204)38-34-81)180-129(222)90(30-20-21-48-154)173-145(238)109(68-198)190-136(229)100(57-82-35-39-86(205)40-36-82)181-139(232)106(62-118(213)214)187-147(240)111(70-200)192-150(243)122(77(9)202)195-142(235)102(55-80-26-16-13-17-27-80)188-149(242)121(76(8)201)193-116(210)66-168-126(219)93(41-44-112(156)206)175-144(237)108(67-197)189-125(218)88(155)59-84-65-164-71-169-84/h12-19,24-29,33-40,64-65,71-78,88,90-111,120-123,167,197-205H,20-23,30-32,41-63,66-70,154-155H2,1-11H3,(H2,156,206)(H2,157,207)(H2,158,208)(H2,159,209)(H,164,169)(H,168,219)(H,170,220)(H,171,217)(H,172,221)(H,173,238)(H,174,239)(H,175,237)(H,176,226)(H,177,241)(H,178,228)(H,179,230)(H,180,222)(H,181,232)(H,182,231)(H,183,224)(H,184,225)(H,185,223)(H,186,227)(H,187,240)(H,188,242)(H,189,218)(H,190,229)(H,191,233)(H,192,243)(H,193,210)(H,194,234)(H,195,235)(H,196,236)(H,211,212)(H,213,214)(H,215,216)(H,244,245)(H4,160,161,165)(H4,162,163,166)/t75-,76+,77+,78?,88-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MASNOZXLGMXCHN-GVLKBUBXSA-N
| InChI = 1S/C153H225N43O49S/c1-72(2)52-97(133(226)176-96(47-51-246-11)132(225)184-104(60-115(159)209)143(236)196-123(78(10)203)151(244)245)179-137(230)103(58-83-64-167-89-29-19-18-28-87(83)89)183-131(224)95(43-46-114(158)208)177-148(241)120(74(5)6)194-141(234)101(54-79-24-14-12-15-25-79)182-138(231)105(61-117(211)212)185-130(223)94(42-45-113(157)207)171-124(217)75(7)170-127(220)91(31-22-49-165-152(160)161)172-128(221)92(32-23-50-166-153(162)163)174-146(239)110(69-199)191-140(233)107(63-119(215)216)186-134(227)98(53-73(3)4)178-135(228)99(56-81-33-37-85(204)38-34-81)180-129(222)90(30-20-21-48-154)173-145(238)109(68-198)190-136(229)100(57-82-35-39-86(205)40-36-82)181-139(232)106(62-118(213)214)187-147(240)111(70-200)192-150(243)122(77(9)202)195-142(235)102(55-80-26-16-13-17-27-80)188-149(242)121(76(8)201)193-116(210)66-168-126(219)93(41-44-112(156)206)175-144(237)108(67-197)189-125(218)88(155)59-84-65-164-71-169-84/h12-19,24-29,33-40,64-65,71-78,88,90-111,120-123,167,197-205H,20-23,30-32,41-63,66-70,154-155H2,1-11H3,(H2,156,206)(H2,157,207)(H2,158,208)(H2,159,209)(H,164,169)(H,168,219)(H,170,220)(H,171,217)(H,172,221)(H,173,238)(H,174,239)(H,175,237)(H,176,226)(H,177,241)(H,178,228)(H,179,230)(H,180,222)(H,181,232)(H,182,231)(H,183,224)(H,184,225)(H,185,223)(H,186,227)(H,187,240)(H,188,242)(H,189,218)(H,190,229)(H,191,233)(H,192,243)(H,193,210)(H,194,234)(H,195,235)(H,196,236)(H,211,212)(H,213,214)(H,215,216)(H,244,245)(H4,160,161,165)(H4,162,163,166)/t75-,76+,77+,78?,88-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-/m0/s1
| InChIKey = MASNOZXLGMXCHN-GVLKBUBXSA-N
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number        = 
| ATCvet            = 
| ATC_prefix        = <!-- 'none' if uncategorised -->
| ATC_suffix        = 
| PubChem = 16186314
| IUPHAR_ligand = 1136
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          = 
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 266481
| chemical_formula  = 
| molecular_weight  = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}

Glucose is stored in the liver in the form of glycogen, which is a starch-like polymer chain made up of glucose molecules. Liver cells ([[hepatocytes]]) have [[glucagon receptor]]s. When glucagon binds to the glucagon receptors, the liver cells convert the glycogen polymer into individual glucose molecules, and release them into the bloodstream, in a process known as [[glycogenolysis]]. As these stores become depleted, glucagon then encourages the liver and kidney to synthesize additional glucose by [[gluconeogenesis]]. Glucagon turns off glycolysis in the liver, causing glycolytic intermediates to be shuttled to gluconeogenesis.

Glucagon also regulates the rate of glucose production through [[lipolysis]]. Glucagon has a minimal effect on [[lipolysis]] in humans.

Glucagon production appears to be dependent on the central nervous system through pathways yet to be defined. In invertebrate animals, [[eyestalk]] removal has been reported to affect glucagon production. Excising the eyestalk in young crayfish produces glucagon-induced hyperglycemia.<ref name="Leinen_1983">{{cite journal | author = Leinen RL, Giannini AJ | title = Effect of eyestalk removal on glucagon induced hyperglycemia in crayfish | journal = Society for Neuroscience Abstracts | year = 1983 | volume = 9 | pages = 604 }}</ref>

===Mechanism of action===
Glucagon binds to the [[glucagon receptor]], a [[G protein-coupled receptor]], located in the [[plasma membrane]]. The conformation change in the receptor activates [[G protein]]s, a heterotrimeric protein with α, β, and γ subunits. When the G protein interacts with the receptor, it undergoes a conformational change that results in the replacement of the [[guanosine diphosphate|GDP]] molecule that was bound to the α subunit with a [[guanosine triphosphate|GTP]] molecule. This substitution results in the releasing of the α subunit from the β and γ subunits.  The alpha subunit specifically activates the next enzyme in the cascade, [[adenylate cyclase]].

Adenylate cyclase manufactures [[cyclic adenosine monophosphate]] (cyclic AMP or cAMP), which activates [[protein kinase A]] (cAMP-dependent protein kinase). This enzyme, in turn, activates [[phosphorylase kinase]], which, in turn, phosphorylates [[glycogen phosphorylase]], converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of [[glucose-1-phosphate]] from glycogen polymers.

== History ==
In the 1920s, Kimball and Murlin studied [[pancreas|pancreatic]] extracts, and found an additional substance with [[hyperglycemia|hyperglycemic]] properties. They described glucagon in 1923.<ref name="Kimball_1923">{{cite journal | author = Kimball C, Murlin J | title = Aqueous extracts of pancreas III. Some precipitation reactions of insulin | journal = J. Biol. Chem. | year = 1923 | volume = 58 | pages = 337–348 | url = http://www.jbc.org/cgi/reprint/58/1/337 | issue=1}}</ref> The amino acid sequence of glucagon was described in the late 1950s.<ref name="Bromer_1957">{{cite journal | author = Bromer W, Winn L, Behrens O | title = The amino acid sequence of glucagon V. Location of amide groups, acid degradation studies and summary of sequential evidence | journal = J. Am. Chem. Soc. | year = 1957 | volume = 79 | issue = 11 | pages = 2807–2810|doi=10.1021/ja01568a038 }}</ref> A more complete understanding of its role in physiology and disease was not established until the 1970s, when a specific [[radioimmunoassay]] was developed.

===Etymology===
Glucagon was named in 1923, probably from the [[Greek (language)|Greek]] ''[[wikt:γλυκός|γλυκός]]'' ''sweet'', and ''[[wikt:ἄγειν|ἄγειν]]'' ''to lead''.<ref>[http://dictionary.reference.com/browse/glucagon glucagon] on [[dictionary.com]]</ref>

==Structure==
Glucagon is a 29-[[amino acid]] [[polypeptide]]. Its [[primary structure]] in humans is: [[amine|NH<sub>2</sub>]]-[[Histidine|His]]-[[Serine|Ser]]-[[Glutamine|Gln]]-[[Glycine|Gly]]-[[Threonine|Thr]]-[[Phenylalanine|Phe]]-[[Threonine|Thr]]-[[Serine|Ser]]-[[Aspartic acid|Asp]]-[[Tyrosine|Tyr]]-[[Serine|Ser]]-[[Lysine|Lys]]-[[Tyrosine|Tyr]]-[[Leucine|Leu]]-[[Aspartic acid|Asp]]-[[Serine|Ser]]-[[Arginine|Arg]]-[[Arginine|Arg]]-[[Alanine|Ala]]-[[Glutamine|Gln]]-[[Aspartic acid|Asp]]-[[Phenylalanine|Phe]]-[[Valine|Val]]-[[Glutamine|Gln]]-[[Tryptophan|Trp]]-[[Leucine|Leu]]-[[Methionine|Met]]-[[Asparagine|Asn]]-[[Threonine|Thr]]-[[carboxyl group|COOH]].

The polypeptide has a [[molecular weight]] of 3485 [[Atomic mass unit|dalton]]s. Glucagon is a [[peptide]] (non[[steroid]]) hormone.

Glucagon is generated from the cleavage of [[proglucagon]] secreted by pancreatic islet α cells. In intestinal L cells, [[proglucagon]] is cleaved to the alternate products [[glicentin]], [[GLP-1]] (an [[incretin]]), [[IP-2]], and [[GLP-2]] (promotes intestinal growth).

==Pathology==
Abnormally elevated levels of glucagon may be caused by pancreatic [[tumor]]s, such as [[glucagonoma]], symptoms of which include [[necrolytic migratory erythema]], reduced amino acids, and [[hyperglycemia]]. It may occur alone or in the context of [[multiple endocrine neoplasia type 1]].

==Uses and contraindications==

===Hypoglycemia===
An injectable form of glucagon is vital first aid in cases of severe hypoglycemia when the victim is unconscious or for other reasons cannot take glucose orally. The dose for an adult is typically 1 milligram, and the glucagon is given by intramuscular, intravenous or subcutaneous injection, and quickly raises [[blood glucose]] levels. Glucagon can also be administered intravenously at 0.25 - 0.5 unit.  To use the injectable form, it must be reconstituted prior to use, a step that requires a sterile diluent to be injected into a vial containing powdered glucagon, because the hormone is highly unstable when dissolved in solution.  When dissolved in a fluid state, glucagon can form amyloid fibrils, or tightly woven chains of proteins made up of the individual glucagon peptides, and once glucagon begins to fibrilize, it becomes useless when injected, as the glucagon cannot be absorbed and used by the body.  The reconstitution process makes using glucagon cumbersome, although there are a number of products now in development from a number of companies that aim to make the product easier to use.

===Beta blocker overdose===
Anecdotal evidence suggests a benefit of higher doses of glucagon in the treatment of overdose with [[beta blocker]]s; the likely mechanism of action is the increase of cAMP in the [[myocardium]], in effect bypassing the [[Adrenergic receptor|β-adrenergic]] [[second messenger system]].<ref name="pmid10234590">{{cite journal | author = White CM | title = A review of potential cardiovascular uses of intravenous glucagon administration | journal = J Clin Pharmacol | volume = 39 | issue = 5 | pages = 442–7 | year = 1999 | month = May | pmid = 10234590 | doi = | url =  }}</ref>

=== Impacted food bolus ===
Glucagon relaxes the [[lower esophageal sphincter]] and is used in emergencies involving an impacted food bolus in the esophagus.<ref name="pmid18925301">{{cite journal |author=Ko HH, Enns R |title=Review of food bolus management |journal=Can. J. Gastroenterol. |volume=22 |issue=10 |pages=805–8 |year=2008 |month=October |pmid=18925301 |pmc=2661297}}</ref>

===Side-effects and interactions===
Glucagon acts very quickly; common side-effects include headache and nausea.

Drug interactions: Glucagon interacts only with oral anticoagulants, increasing the tendency to bleed.

===Contraindications===
While glucagon can be used clinically to treat various forms of hypoglycemia, it is severely contraindicated in patients with [[pheochromocytoma]], as the drug interaction with elevated levels of [[adrenaline]] produced by the tumor may produce an exponential increase in blood sugar levels, leading to a hyperglycemic state, which may incur a fatal elevation in blood pressure.<ref name="urlpi.lilly.com">{{cite web | url = http://pi.lilly.com/us/rglucagon-pi.pdf | title =  Information for the Physician: Glucagon for Injection (rDNA origin) | date = | format = | work = | publisher = Eli Lilly and Company | accessdate = 2011-11-19 }}</ref> Likewise, glucagon is contraindicated in patients with an [[insulinoma]], as its use may lead to rebound [[hypoglycemic|hypoglycemia]].<ref name="urlpi.lilly.com"/>

==Media==
[[Image:Glucagon stereo animation.gif|thumb|center|Rotating [[stereogram]] animation of glucagon (1.70 [[Megabyte|MB]], [[animated GIF]] format)]]

==See also==
* [[Cortisol]]
* [[Diabetes mellitus]]
* [[Glucagon-like peptide-1]]
* [[Glucagon-like peptide-2]]
* [[Insulin]]
* [[Islets of Langerhans]]
* [[Pancreas]]
* [[Proglucagon]]

==References==
{{Reflist|35em}}

==Further reading==
{{refbegin|35em}}
*{{cite journal  | author=Kieffer TJ, Habener JF |title=The glucagon-like peptides |journal=Endocr. Rev. |volume=20 |issue= 6 |pages= 876–913 |year= 2000 |pmid= 10605628 |doi=10.1210/er.20.6.876  }}
*{{cite journal  | author=Drucker DJ |title=Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis |journal=Mol. Endocrinol. |volume=17 |issue= 2 |pages= 161–71 |year= 2003 |pmid= 12554744| doi=10.1210/me.2002-0306}}
*{{cite journal  | author=Jeppesen PB |title=Clinical significance of GLP-2 in short-bowel syndrome |journal=J. Nutr. |volume=133 |issue= 11 |pages= 3721–4 |year= 2004 |pmid= 14608103 |doi=  }}
*{{cite journal  | author=Brubaker PL, Anini Y |title=Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2 |journal=Can. J. Physiol. Pharmacol. |volume=81 |issue= 11 |pages= 1005–12 |year= 2004 |pmid= 14719035 |doi= 10.1139/y03-107 }}
*{{cite journal  | author=Baggio LL, Drucker DJ |title=Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2 |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=18 |issue= 4 |pages= 531–54 |year= 2005 |pmid= 15533774 |doi= 10.1016/j.beem.2004.08.001 }}
*{{cite journal  | author=Holz GG, Chepurny OG |title=Diabetes Outfoxed by GLP-1? |journal=Sci. STKE |volume=2005 |issue= 268 |pages= pe2 |year= 2006 |pmid= 15671479  | pmc=2909599 |doi= 10.1126/stke.2682005pe2 }}
*{{cite journal  | author=Dunning BE, Foley JE, Ahrén B |title=Alpha cell function in health and disease: influence of glucagon-like peptide-1 |journal=Diabetologia |volume=48 |issue= 9 |pages= 1700–13 |year= 2006 |pmid= 16132964 |doi= 10.1007/s00125-005-1878-0 }}
*{{cite journal  | author=Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C |title=Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes |journal=Diabetes Metab. |volume=31 |issue= 3 Pt 1 |pages= 233–42 |year= 2005 |pmid= 16142014| doi=10.1016/S1262-3636(07)70190-8}}
*{{cite journal  | author=De León DD, Crutchlow MF, Ham JY, Stoffers DA |title=Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus |journal=Int. J. Biochem. Cell Biol. |volume=38 |issue= 5–6 |pages= 845–59 |year= 2006 |pmid= 16202636 |doi= 10.1016/j.biocel.2005.07.011 }}
*{{cite journal  | author=Beglinger C, Degen L |title=Gastrointestinal satiety signals in humans--physiologic roles for GLP-1 and PYY? |journal=Physiol. Behav. |volume=89 |issue= 4 |pages= 460–4 |year= 2007 |pmid= 16828127 |doi= 10.1016/j.physbeh.2006.05.048 }}
*{{cite journal  | author=Stephens JW, Bain SC |title=Safety and adverse effects associated with GLP-1 analogues |journal=Expert opinion on drug safety |volume=6 |issue= 4 |pages= 417–22 |year= 2007 |pmid= 17688385 |doi= 10.1517/14740338.6.4.417 }}
*{{cite journal  | author=Orskov C |title=Complete sequences of glucagon-like peptide-1 from human and pig small intestine |journal=J. Biol. Chem. |volume=264 |issue= 22 |pages= 12826–9 |year= 1989 |pmid= 2753890 |doi=  | author-separator=,  | author2=Bersani M  | author3=Johnsen AH  | display-authors=3  | last4=Højrup  | first4=P  | last5=Holst  | first5=JJ  }}
*{{cite journal  | author=Drucker DJ, Asa S |title=Glucagon gene expression in vertebrate brain |journal=J. Biol. Chem. |volume=263 |issue= 27 |pages= 13475–8 |year= 1988 |pmid= 2901414 |doi=  }}
*{{cite journal  | author=Novak U, Wilks A, Buell G, McEwen S |title=Identical mRNA for preproglucagon in pancreas and gut |journal=Eur. J. Biochem. |volume=164 |issue= 3 |pages= 553–8 |year= 1987 |pmid= 3569278| doi=10.1111/j.1432-1033.1987.tb11162.x}}
*{{cite journal  | author=White JW, Saunders GF |title=Structure of the human glucagon gene |journal=Nucleic Acids Res. |volume=14 |issue= 12 |pages= 4719–30 |year= 1986 |pmid= 3725587| doi=10.1093/nar/14.12.4719  | pmc=311486}}
*{{cite journal  | author=Schroeder WT, Lopez LC, Harper ME, Saunders GF |title=Localization of the human glucagon gene (GCG) to chromosome segment 2q36----37 |journal=Cytogenet. Cell Genet. |volume=38 |issue= 1 |pages= 76–9 |year= 1984 |pmid= 6546710 |doi=10.1159/000132034  }}
*{{cite journal  | author=Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC |title=Exon duplication and divergence in the human preproglucagon gene |journal=Nature |volume=304 |issue= 5924 |pages= 368–71 |year= 1983 |pmid= 6877358| doi=10.1038/304368a0}}
*{{cite journal  | author=Kärgel HJ |title=Action of rat liver cathepsin L on glucagon |journal=Acta Biol. Med. Ger. |volume=40 |issue= 9 |pages= 1139–43 |year= 1982 |pmid= 7340337 |doi=  | author-separator=,  | author2=Dettmer R  | author3=Etzold G  | display-authors=3  | last4=Kirschke  | first4=H  | last5=Bohley  | first5=P  | last6=Langner  | first6=J  }}
*{{cite journal  | author=Wayman GA |title=Synergistic activation of the type I adenylyl cyclase by Ca2+ and Gs-coupled receptors in vivo |journal=J. Biol. Chem. |volume=269 |issue= 41 |pages= 25400–5 |year= 1994 |pmid= 7929237 |doi=  | author-separator=,  | author2=Impey S  | author3=Wu Z  | display-authors=3  | last4=Kindsvogel  | first4=W  | last5=Prichard  | first5=L  | last6=Storm  | first6=DR  }}
*{{cite journal  | author=Unson CG, Macdonald D, Merrifield RB |title=The role of histidine-1 in glucagon action |journal=Arch. Biochem. Biophys. |volume=300 |issue= 2 |pages= 747–50 |year= 1993 |pmid= 8382034 |doi= 10.1006/abbi.1993.1103 }}
{{refend}}

{{PDB Gallery|geneid=2641}}
{{Hormones}}
{{Proglucagon}}

[[Category:Eli Lilly and Company]]
[[Category:Peptide hormones]]
[[Category:Pancreatic hormones]]
[[Category:Hepatology]]
[[Category:Metabolism]]
[[Category:Human hormones]]
[[Category:Hormones of glucose metabolism]]